GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
暂无分享，去创建一个
J. Gribben | G. Salles | B. Cheson | P. Lugtenburg | M. Trněný | O. Press | J. Mayer | N. Fowler | G. Fingerle-Rowson | N. Chua | G. Dueck | K. Bouabdallah | V. Delwail | A. Lennard | N. Franklin | Elisabeth Wassner Fritsch